drugset / Trial / NCT04131218

Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade

NCT04131218

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to illustrate pharmacokinetics and pharmacodynamics of sugammadex in reversal of vecuronium-induced neuromuscular blockade in anesthesia obese patients undergoing bariatric surgery.

Timeline

Start
2019-07-16
Primary completion
2020-07
Completion
2020-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sugammadex Other / unclassified 2 mg/kg

Indications

No indication recorded.